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Abstract
Variations in the activities of Cytochrome P450s are one of the major factors responsible for inter-individual differences in
drug clearance rates, which may cause serious toxicity or inefficacy of therapeutic drugs. Various mRNA level is one of the
key factors for different activity of the major P450 genes. Although both genetic and environmental regulators of P450 gene
expression have been widely investigated, few studies have evaluated the functional importance of cis- and trans-regulatory
factors and environmental factors in the modulation of inter-individual expression variations of the P450 genes. In this study,
we measured the mRNA levels of seven major P450 genes (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5)
in 96 liver biopsy samples from Chinese population. Both trans-acting (mRNA levels and non-synonymous SNPs of putative
regulator genes) and cis-acting (gene copy number and functional SNPs) factors were investigated to identify the
determinants of the expression variations of these seven P450 genes. We found that expression variations of most P450
genes, regulator genes and housekeeping genes were positively correlated at the mRNA level. After partial correlation
analysis using ACTB and GAPDH expression to eliminate the effect of global regulators, a UPGMA (Unweighted Pair Group
Method with Arithmetic Mean) tree was constructed to reveal the effects of specific regulation networks potentially masked
by global regulators. Combined with the functional analysis of regulators, our results suggested that expression variation at
the mRNA level was mediated by several factors in a gene-specific manner. Cis-acting genetic variants might play key roles
in the expression variation of CYP2D6 and CYP3A5, environmental inducers might play key roles in CYP1A1 and CYP1A2
variation and global regulators might play key roles in CYP2C9 variation. In addition, the functions of regulators that play
less important roles in controlling expression variation for each P450 gene were determined.
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Introduction
The Cytochrome P450 superfamily is a very large and diverse
group of hemoproteins that is present in almost all living
organisms. About 57 putative functional Cytochrome P450 genes
and more than 58 pseudogenes have been identified in the human
genome [1,2]. These P450 genes encode enzymes, such as
monooxygenase, that play a crucial role in detoxification of
exogenous xenobiotics, decomposition of drugs and metabolism of
many endogenous compounds, such as hormones, fatty acids,
prostaglandin, cholesterol and vitamin D [3,4]. It is well
recognized that inter-individual variability in activity of the P450
enzymes is a major factor responsible for inter-individual
variations in drug clearance rates [5]. Cytochrome P450 enzymes,
which play key roles in Phase I oxidative metabolism, have been
extensively investigated due to their great variations in activity in
the human population. The inter-individual variability in the total
activity of P450s is primarily caused by polymorphisms that affect
activity and expression. Strong correlations between expression
level and enzyme activity have been observed for CYP1A1,
CYP1A2, CYP3A4, CYP2C8, CYP2C9, CYP2D6 and CYP2B6,
suggesting that the mRNA level may be a major determinant of
the total activity of these P450 genes [6,7].
Ten- to a hundred-fold inter-individual differences in expression
levels have been observed for most Cytochrome P450 genes [6,8].
Most of the P450s that metabolize exogenous compounds are
highly expressed in the human liver, but some P450 forms are
expressed at low levels in extrahepatic tissues. The mechanisms
underlying the maintenance and regulation of the high expression
levels of the P450 genes in the liver are not completely understood.
Data have shown that the expression levels of some liver-enriched
transcription factors, such as the Constitutive Androstane
Receptor (CAR), Hepatic Nuclear Factor 4a (HNF4a) and P450
Oxidoreductase (POR), may determine the variability in the basal
expression and activity of a broad range of P450 genes [8]. In
addition, P450 gene-specific mechanisms have been identified. For
example, activation of the aryl hydrocarbon receptor (AHR)-
mediated pathway induces an increase in expression of the
CYP1A1 and CYP1A2 genes [9,10]; for CYP2D6 and CYP2A6, copy
number variation and some regulatory alleles have been reported
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phism in CYP3A5, the CYP3A5*3 allele, is the major factor that
modulates expression [13]. Despite the tremendous amount of
research that has been performed to construct the regulatory
network of P450 genes, few studies have evaluated the functional
importance of various factors in controlling P450 expression
variation among individuals.
In this study, we systematically evaluated the determinants of P450
expression variation among individuals. We measured the absolute
expression levels of three housekeeping genes (18S rRNA,GAPDH and
ACTB), seven P450 genes (CYP1A1, CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP3A4 and CYP3A5) and seven putative Cytochrome
P450 regulator genes (USF1, CAR, PXR, HNF4A, HNF1A, AHR and
ARNT) (for full names of these genes, refer to Table S1). Pairwise
correlation analysis was performed to explore the network of
interaction among these genes. The gene-gene interactions and
gene-environment interactions made it difficult to distinguish the
effects of each regulatory factor. Therefore, allelic expression ratios
(AERs) of CYP1A1, CYP1A2, CYP2C9, CYP2C19 and CYP3A4 were
measured using two SNP markers from each gene to determine the
presence of cis-acting regulatory variants [14–17]. The copy number
of CYP2D6 was determined, and the correlation between the copy
number and mRNA level of CYP2D6 was examined. Fifteen SNPs
located in the seven P450 genes and three regulator genes (Table S2)
were typed and tested for association with the expression levels of the
corresponding P450 genes.
Results
Expression variations in the P450s and regulatory genes
The mRNA levels of two putative housekeeping genes (GAPDH
and ACTB),sevenP450 genes (CYP1A1,CYP1A2,CYP2C9,CYP2C19,
CYP2D6, CYP3A4 and CYP3A5) and seven regulatory genes (USF1,
CAR, PXR, HNF1A, HNF4A, AHR and ARNT) were determined by
quantitative real-time PCR and normalized to 18S rRNA expression.
Up to 8- to 10-fold inter-individual differences were observed for
GAPDH and ACTB (Table S4). This result raised doubts about the
applicability of GAPDH and ACTB as reference genes. Thus, 18S
rRNA was selected as the reference gene based on two observations: 1)
the 18S rRNA level had the lowest CV(coefficient of variation) as
shown in Fig. 1 and 2) the 18S rRNA level is strongly correlated
(r=0.76) with the cDNA level of USF1, which had the second lowest
CV and encodes a ubiquitous transcription factor.
In our samples, all regulatory genes were constitutively transcribed
at low levels with low inter-individual variability (,7-fold), whereas
most P450 genes showed much greater inter-individual variability
(.13-fold), except for CYP2C9 (7.2-fold). The expression levels of the
seven P450 genes were CYP3A4.CYP2C9.CYP2D6.CYP1A2.-
.CYP2C9.CYP2D6.CYP1A2.CYP3A5.CYP2C19.CYP1A1 (Ta-
ble S4). The expression variations were CYP1A1.CYP2D6<YCY-
.CYP2D6<YCYP3A4.CYP2C19.CYP3A5<CYP1A2.CYP2C9
(Table S4). One sample with no CYP2D6 expression was excluded
from the variation comparison due to the loss of both CYP2D6 alleles
(as discussed later). In some individuals, extreme differences in
expression levels were observed for CYP3A4,CYP2D6 and CYP1A1 by
comparison of the T5/B5 and Max/Min ratios. The T5/B5 ratio
denotes the ratio of the average expression level of the top 5% of
samples to that of the bottom 5% of samples. There was more than a
5-fold difference between these two ratios for CYP3A4 (Table S4).
Correlations among mRNA levels of P450 and regulator
genes
Interestingly, the expression levels of almost all of the genes
(including GAPDH and ACTB) were strongly correlated with each
other at the mRNA level (Table S5). Such correlations may be the
result of powerful global regulators. Thus, we conducted a partial
correlation analysis using the mRNA levels of both GAPDH and
ACTB to eliminate or reduce these effects. After the partial
correlation analysis, the degree of most correlations was largely
reduced, and many were not significant (p.0.05) (Table S6).
However, strong correlations were still observed between CYP1A1
and CYP1A2 (r=0.81); CYP2C9 and CAR (r=0.66), PXR
(r=0.57), HNF1A (r=0.50) and ARNT (r=0.57); among ARNT,
HNF1A, HNF4A, PXR and CAR (r.0.44) and among CYP2C9,
CYP2C19 and CYP3A4 (r.0.44).These correlations remained
significant after adjustment for age and smoking history in
multivariate logistic regression analysis (padj,0.001). A UPGMA
(Unweighted Pair Group Method with Arithmetic Mean) tree
(Fig. 2) was constructed based on the partial correlation matrix,
and three clusters were roughly defined. The first cluster was
composed of five regulator genes (HNF1A, HNF4A, CAR, PXR and
ARNT), the second contained CYP2C9, CYP3A4 and CYP2C19 and
the third included only CYP1A1 and CYP1A2.
Copy number variation and expression level of CYP2D6
The copy number of CYP2D6 varied from 0 to 9 among the 92
DNA samples (Fig. 3). Four samples were excluded due to
inconsistency between measurements using different CYP2D6
primers or without mRNA. One sample containing a homozygous
CYP2D6 deletion (CYP2D6*5) was identified. The mRNA level of
CYP2D6 is plotted against copy number in Fig. 3. Higher copy
numbers tended to increase the expression level in samples with
#4 copies. A strong correlation (r=0.63, p,0.0001) was observed
between copy number and expression level for samples with no
more than four copies of CYP2D6. The correlation remained
significant after adjustment for age and smoking history in
multivariate logistic regression analysis (padj,0.001).
Association analysis between genetic variants in P450s
and regulator genes and mRNA levels of seven P450
genes
Expression variations in the P450 genes may result from the
different activities of regulator protein isoforms in addition to
different protein levels. All three non-synonymous SNPs in the
regulatory genes mentioned above with MAF (minor allele
frequency).5% in the Chinese population were genotyped in 96
liver samples. These three SNPs, two (rs1169288 and rs2464196)
in HNF1A and one (rs2066853) in AHR, were not associated with
the expression levels of any of the seven P450 genes examined,
which indicates that the polymorphisms of HNF1A and AHR do
not contribute to the expression variations of these seven P450
genes. In total, 12 marker SNPs in the P450 genes (Table S2) used
for allelic expression imbalance (AEI) detection were tested for
association with mRNA levels. Rs776746 (also known as
6986G.A) in CYP3A5, an A.G substitution in intron 3 that
causes aberrant splicing, was strongly correlated with the mRNA
level of CYP3A5 (r=0.506, Fig. 4). The correlations remained
significant after adjustment for age and smoking history in
multivariate logistic regression analysis (padj,0.001). Marginal
associations were observed between rs17861162 and the CYP1A2
mRNA level (p=0.044); rs1934967 and the CYP2C9 mRNA level
(p=0.025) and rs33972239 and the CYP3A4 mRNA level
(p=0.036) by the Kruskal-Wallis test but not by ANOVA. There
was also a marginal association between rs4244285 and the
CYP2C19 mRNA level (p=0.047) detected by ANOVA but not by
the Kruskal-Wallis test. These associations were no longer
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multivariate logistic regression analysis (padj.0.05).
Discussion
Expression variations of P450s and regulator genes
CYP1A1 showed the largest inter-individual difference in
expression (138-fold, Table S4), which is consistent with the
observation that expression of CYP1A1 was highly inducible by
environmental inducers. The levels of inter-individual expression
variability observed in this study for most of the P450 genes and
some regulatory genes were much lower than those found in several
previous studies [6,8]. For example, an approximately 6-fold
difference was detected in our samples for CAR, but Wortham et
al.[8] reported a 145-folddifference.This studyfounddifferences of
approximately 14- and 64-fold for CYP1A2 and CYP3A4, respec-
tively, whereas differences of 582- to 3638-fold were reported for
CYP1A2 and differences of 860- to 1281-fold were reported for
CYP3A4 by Wortham et al. [8] and Rodrı ´guez-Antona et al. [6],
respectively. Some studies have found levels of variability similar to
our results, such as differences of 118-fold and approximately 15-
fold for CYP3A4 [2] and CYP1A2 [18], respectively.
Figure 1. Coefficients of variation of transcript molecule numbers in 96 Chinese liver biopsy samples for 17 genes tested.
doi:10.1371/journal.pone.0024900.g001
Figure 2. A UPGMA tree showing the relationships between 14 genes based on expression levels. Spearman’s correlation coefficients
between the mRNA levels of seven P450s and seven regulator genes were identified using SPSS15.0. A distance matrix was constructed from the
negative natural logarithm of the absolute value of the correlation coefficient, and the UPGMA tree was constructed from this distance matrix with
MEGA 4.0. Three clusters were well defined: one containing CYP1A1 and CYP1A2; one containing CYP2C9, CYP2C19 and CYP3A4 and one containing
HNF4A, HNF1A, ARNT, PXR and CAR.
doi:10.1371/journal.pone.0024900.g002
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differences in ethnic groups, environmental factors, RNA quality
and experiment design. In our study, the samples were obtained
from Chinese Han healthy liver donors and treated with the
protocols recommended by Qiagen. Most primers were designed
in a region close to the 39 end of the mRNA to amplify a short
fragment of 60–180 bp in length, which should reduce the
variation resulting from low RNA quality. Moreover, all SNPs in
the sequences used for primer design were masked first by
performing a BLAST search of the SNP database; therefore, the
primers did not harbor any SNP, which prevented differences in
amplification efficacies due to cDNA samples with different
genotypes at SNPs located within primer sequences.
In our study, measures were taken to reduce the noise effects of
non-genetic factors. Besides the genetic factors, the inter-individual
mRNA expression variations of P450 may be due to differences in
gender, age, food intake, drug treatment, smoking, alcohol using
etc. All the subjects recruited in this study were males and between
30 to 45 years old. According to the donors’ statements, no drugs
were taken before the surgeries for at least 30 days. Alcohol using
and smoking were prohibited 30 days prior to surgery, which
avoided the confounding by alcohol using and smoking.
Multivariate logistic regression was used to adjust for potential
confounding factors including age and smoking history.
However, differences in the food intake of the 96 participants
were not considered, which might be a resource of bias in our
study. Additionally, the expression variation caused by rare alleles
may not be evident in our limited sample size. Thus, further
studies are needed to demonstrate the expression variations of the
P450s in larger sample sizes to eliminate bias.
Coexpression analysis
Unexpectedly, strong correlations were detected among almost
all genes examined in this study, including GAPDH and ACTB,
which were not thought to be involved in the P450 regulation
network (Table S5). Yang et al. [7] suggested that liver P450s are
situated at the center of many endocrine and xenobiotic metabolic
pathways, which require cross talk among numerous nuclear
receptor networks. Alternatively, it is also reasonable to assume
that this correlation may be caused by powerful global regulatory
factors that control expression of most active genes, which would
mask the true regulation network of P450s and the corresponding
regulator genes. Such global regulatory factors are most likely
basic transcription factors and ubiquitous chromatin modifiers.
We performed a partial correlation analysis using the expression
levels of GAPDH and ACTB as controls for the elimination of the
presumed effect. Not surprisingly, 39% of the correlations were
eliminated (Table S6). Based on the remaining ‘‘corrected’’
correlations, we performed a cluster analysis and constructed the
UPGMA tree with MEGA 4 [19]. Finally, three clusters were
roughly identified (Fig. 2).
In cluster I, strong correlations remained among CAR, PXR,
HNF1A, HNF4A and ARNT (Fig. 2), which suggested that there
was co-regulation or interaction among these genes. HNF1A,
Figure 3. Relationship between copy number and the mRNA level of CYP2D6. Both deletion and multiple duplications of CYP2D6 were
observed in the 96 samples. One, seven and fourteen samples were identified as 0, 1 and §5 copies of CYP2D6, respectively. Increasing copy
numbers tended to increase the expression level for samples with ,5 copies but not for those with §5 copies.
doi:10.1371/journal.pone.0024900.g003
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correlations with CAR (r=0.67), PXR (r=0.66) and ARNT
(r=0.63), indicating that HNF1A may be important for regulating
the expression of CAR, PXR and ARNT. Of all of the correlations
between HNF4A and other regulator genes, the correlation
between HNF4A and HNF1A was the strongest (r=0.545), which
is consistent with the observation that HNF1A is regulated by
HNF4A. Regulation of PXR by HNF1A is supported by a previous
report that a putative HNF1A binding site is present in the human
PXR promoter and a 6-bp deletion at this site diminished the
activity of hPAR-2, one of the PXR transcripts [22]. However,
limited data have uncovered a relationship between HNF1A and
CAR or ARNT. Here, we propose a simplified regulation network
among CAR, PXR, HNF1A, HNF4A and ARNT, in which HNF4A
regulates the expression of HNF1A, and HNF1A further regulates
the expression of CAR, PXR and ARNT. Other interactions among
HNF4A, ARNT, CAR and PXR are possible, and more data must be
collected to evaluate this hypothesis. Clusters II and III showed co-
expression of the P450 genes. Because P450s are evolved from a
common ancestor gene, the correlations among the P450 genes
[1,7,23] might result from the shared regulatory factors. CYP1A1
and CYP1A2 in cluster III are orientated in a head-to-head
configuration on 15q22-q24. The 23.3 kb intergenic region might
harbor certain element with a role in co-regulation of the
expression of CYP1A1 and CYP1A2 [24]. However, the correlation
did not entirely agree with the sequence similarity [1]. The effects
of specific regulatory factors on each P450 gene are discussed in
detail below.
CYP1A1 and CYP1A2
CYP1A2 is constitutively expressed in the liver. CYP1A2 and
CYP1A1 are induced by various types of environmental chemicals,
such as PAHs (polycyclic aromatic hydrocarbons), HAAs (hetero-
cyclic aromatic amines amides) and HAHs (halogenated aromatic
hydrocarbons) via the ligand-activated AHR-ARNT pathway. A
strong correlation (r=0.81) between the expression levels of
CYP1A1 and CYP1A2 demonstrated that the two CYP1A genes are
co-regulated. However, the mRNA levels of CYP1A1 and CYP1A2
were not correlated with those of most of the regulator genes,
except for the weak correlations observed between CYP1A1 and
USF1 (p=0.037) and between CYP1A2 and AHR (p=0.025), CAR
(p=0.024) and USF1 (p=0.009), which indicate that environ-
mental inducers involved in activation of the AHR-ARNT
pathway may be an important determinant for the variability in
mRNA levels of CYP1A1 and CYP1A2. Quantitation of the active
and total AHR protein levels may provide direct evidence to
support this hypothesis. Cis-acting variants may also account for
the variations, albeit it to a small extent, as described in Fig. 5.
These cis-acting variants were estimated to induce inter-individual
expression differences of only ,2.5-fold for CYP1A1 and ,1.7-fold
for CYP1A2, compared with a total variability in mRNA level of
138-fold for CYP1A1 and 14-fold for CYP1A2. After exclusion of
Figure 4. Correlation between genotypes at rs776746 and the expression level of CYP3A5. A is the wild-type allele and G is the mutant
allele (CYP3A5*3), which results in aberrant splicing. The natural logarithm of the mRNA data was used for ANOVA analysis. r denotes the Spearman’s
correlation coefficient. The Boxplot displays the minimal, lower quartile, median, upper quartile, maximal points and outliers (marked by circle and
sample No.).
doi:10.1371/journal.pone.0024900.g004
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individual expression difference was about 9-fold, and thus the cis-
acting genetic variants may account for up to 20% of the inter-
individual variability. Therefore, the major determinants for
variability in the expression levels of CYP1A1 and CYP1A2 may
include environmental factors involved in activation of the AHR-
ARNT pathway, global regulators as described above and, to a
lesser extent, cis-acting variants.
CYP2C9
CYP2C9 is the most abundant CYP2C subfamily isozyme in
human liver [25–27]. Expression of CYP2C9 has been reported to
be regulated by a wide range of liver-enriched transcription
factors, such as CAR, PXR and HNF4A [28]. Significant
correlations between the mRNA levels of CYP2C9 and all seven
regulator genes, especially CAR, PXR, ARNT and HNF1A (r.0.5),
were observed, which provides evidence that expression of
putative P450 regulator genes contributes to the inter-individual
variability of CYP2C9 expression levels. Although HNF4A has
been reported to regulate CYP2C9 expression, our results suggest
that HNF1A may play a more important role in the regulation of
CYP2C9 expression than HNF4A because a stronger correlation
was observed between the mRNA levels of CYP2C9 and HNF1A
than between those of CYP2C9 and HNF4A (Table S4). In
addition, our study shows for the first time that ARNT may be an
important regulator of CYP2C9. Strong correlations among
CYP2C9, CYP2C19 and CYP3A4 support the reports that these
three genes are co-regulated by CAR and PXR [29]. No
significant common cis-acting genetic variants were detected for
CYP2C9 (Fig. 5), which is consistent with previously reported data
[17]. In conclusion, of the seven P450 genes examined, CYP2C9
displayed the least expression variation in 96 Chinese liver biopsy
samples, and the variability in expression was mainly determined
by expression of P450 regulator genes, such as CAR, PAR,
HNF1A and ARNT, in addition to the global regulators as
described above. Environmental inducers may also account for
some variation in CYP2C9 expression by activating CAR or PXR.
CYP2C19
Up to 45-fold inter-individual differences were detected for
CYP2C19 among the 96 Chinese liver samples. Only low
correlations between CYP2C19 and several regulator genes
(PXR, CAR, ARNT and HNF1A) were observed. The genetic
variant CYP2C19*2 at rs4244285, which results in aberrant
splicing, may account for up to 2-fold allelic expression difference
(Fig. 5); however, only a weak association was detected between
rs4233285 and the mRNA levels of CYP2C19 by ANOVA.
Therefore, the inter-individual variability in the mRNA levels of
CYP2C19 (up to 45-fold) may be largely determined by factors
other than cis-acting genetic variants or the mRNA levels of
regulator genes.
CYP2C19 is highly induced by drugs, such as rifampin, via
activation of the CAR/PXR-mediated pathway [29]. Strong
correlations were found among the mRNA levels of three target
genes of CAR/PXR: CYP2C19, CYP2C9 and CYP3A4. However,
slight correlations between the mRNA levels of CYP2C19 and CAR
and PXR suggest the importance of CAR/PXR activation by
CYP2C19 inducers in modulating the expression of CYP2C19.
Quantitation of the active and total CAR or PXR protein levels
may provide further evidence for this hypothesis. Therefore, the
major determinants for the inter-individual variability in the
mRNA levels of CYP2C19 may include global regulators and
environmental inducers for activation of the CAR/PXR pathway.
To a lesser extent, cis-acting genetic variants or the mRNA levels
of CAR and PXR may account for a small part of the expression
variation of CYP2C19.
Figure 5. Distribution of allelic expression ratios of five P450 genes. M01 to M10 denotes markers SNP 1 to 10, which are rs1048943,
rs4646421, rs17861162, rs762551, rs4388808, rs4244285, rs1934967, rs1934969, rs2246709 and rs33972239, respectively, in CYP1A1, CYP1A2,
CYP2C19, CYP2C9 and CYP3A4. The marker SNP is either intronic or exonic, and the ratio of two alleles of marker SNP in the cDNA is representative of
the allelic expression ratio of the corresponding gene. The upper and lower dashed lines indicate AERs of 1.2 and 0.8, respectively. In general, an AER
of less than 0.8 or greater than 1.2 is experientially indicative of allelic expression imbalance.
doi:10.1371/journal.pone.0024900.g005
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A substantial inter-individual difference was identified (up to 68-
fold without inclusion of a sample homozygous for CYP2D6
deletion) at the mRNA level for CYP2D6. Slight correlations were
observed between CYP2D6 and several regulator genes (PXR, CAR,
HNF4A and ARNT) at the mRNA level, demonstrating that the
mRNA levels of regulator genes contribute to the variability in
expression of CYP2D6 (Table S6), albeit to a much lesser extent
compared with CYP2C9. The global factor that affected expression
of most of the other genes played a less important role in CYP2D6
expression (Table S6). The copy number of functional CYP2D6
was the major determinant of the variability in the mRNA levels of
CYP2D6 (Fig. 3). The P450 regulator genes and global regulators
may make some contributions but to lesser extents.
The correlation between the copy number and mRNA level of
CYP2D6 was not consistent when the copy number is more than
four in this study. The inconsistency may attribute to two reasons.
First, the inconsistency may be caused by the insufficient sample
size. Thirteen samples with more than four copies of CYP2D6 were
investigated in current study. Even larger sample size is needed in
the further study to validate whether this inconsistency is true.
Second, the CYP2D6 gene duplications include functional, partly
functional and nonfunctional genes, which could cause splicing
defeat or produce unstable mRNA [30–32]. It is possible that the
samples in our study with more than four CYP2D6 copies contain
partly functional or nonfunctional gene copies, which results in this
inconsistency. Further long range PCR and clone sequencing are
needed to clarify this issue.
CYP3A4
High expression levels and high inter-individual expression
differences were observed in CYP3A4. The slight correlations
observed between CYP3A4 and several regulator genes (PXR, CAR,
HNF1A and ARNT) at the mRNA level indicated that regulator
genes have moderate effects on CYP3A4 expression variation
(Table S6). CYP3A4 is highly induced by drugs, such as rifampin,
via activation of the CAR/PXR-mediated pathway. Similarly to
CYP2C19, the determinants for the expression variability of
CYP3A4 may be global regulators, environmental inducers that
activate CAR/PXR and, to a lesser extent, the mRNA levels of the
CAR and PXR genes. Some rare cis-acting genetic variants might
induce up to 2-fold inter-individual expression differences;
however, only a very small proportion of samples (4%) was
affected (Fig. 5). Thus, these genetic variants contribute little to the
variability in the mRNA levels of CYP3A4. In summary, the
determinants for the expression variability of CYP3A4 may be
global regulators, environmental inducers that activate CAR/
PXR and, to a lesser extent, the mRNA levels of the CAR and PXR
genes.
CYP3A5
No correlations were observed between the mRNA levels of
CYP3A5 and the regulatory genes. A strong association (p,0.0001,
Fig. 4) was identified between the mRNA levels of CYP3A5 and
rs776746, which is the CYP3A5*3 allele that induces aberrant
splicing of CYP3A5. The unstable mRNA produced by aberrant
splicing decreases the expression level. Thus, this cis-acting
element is another determinant of CYP3A5 expression variation
in addition to global regulators.
Based on the data reported here, we propose that at least four
factors are determinants of the expression variation of P450 genes
(Table 1): I) global regulators that affect the expression levels of
most active genes, which are most likely basic transcription factors
and ubiquitous chromatin modifiers; II) P450-specific regulators;
III) environmental inducers responsible for the activation of P450-
specific regulators and IV) genetic variants of the P450 genes,
including gene duplication or deletion. In our study, we weighed
the functional importance of each factor on the expression
variation of each P450 gene.
In summary, we functionally evaluated several factors that
control the variability in the mRNA levels of CYP1A1, CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5. Moreover,
the variations in the mRNA levels of 7 P450 genes characterized in
96 Chinese liver samples in this study provide useful data on the
liver P450s in Asian populations, which traditionally have not been
analyzed in European-based studies.
Although strong correlations were observed between the mRNA
level and certain variants (CYP3A5 and rs776746; CYP2D6 and the
copy number), such genetic variation is not good enough to be
used clinically in the individual patient. The activities of drug-
metabolizing enzymes are regulated at many levels except for
genetic factors. Further studies should be done before the
application of the research conclusions in clinical practice.
Materials and Methods
Ethics Statement
All participants gave written informed consent. The acquisition
of all data using samples from these participants was approved by
the Ethics Review Committee of the Chinese National Human
Genome Center at Shanghai.
Human Liver Tissues
A total of 96 human liver biopsy samples were obtained in
Tianjin First Center Hospital from donor livers that were
morphologically normal and tested negative for HIV (human
immunodeficiency virus) and hepatitis. All the subjects recruited in
this study were males and between 30 to 45 years old. According
to the donors’ statements, no drugs were taken before the surgeries
for at least 30 days. Alcohol using and smoking were prohibited 30
days prior to surgery. About 50–200 mg of tissue for each sample
was immediately submerged in RNAlater (Sigma-Aldrich) after
collection from live livers during liver transplant surgery. After
storage overnight in RNAlater at 4uC, all samples were stored at
270uC until the DNA and RNA extractions were performed.
Isolation of DNA and Total RNA from Human Liver
Tissues
Tissues in RNAlater were thawed at room temperature, washed
with DEPC-treated water and homogenized in 1 ml Trizol
(Invitrogen) using a Pro200 homogenizer (Pro Scientific Inc.).
Both DNA and total RNA were extracted according to the
manufacturer’s protocol. Extracted DNA and total RNA were
quantitated using a Biophotometer (Eppendorf). Total RNA was
purified by DNase I (Takara) treatment followed by phenol/
chloroform extraction and ethanol precipitation. Purified RNA
was dissolved in DEPC-treated water, quantitated, diluted to
approximately 1 mg/ml and stored at 270uC.
Absolute Quantitation of mRNA level by Real-time PCR
All primers for real-time quantitative PCR were designed to
specifically amplify fragments of 80–180 bp in length inside single
exons using the online program Primer3 (http://frodo.wi.mit.edu/
primer3/input.htm). The sequence for each primer is listed in
Table S3. Reverse transcription reactions were prepared in a total
volume of 20 ml containing 16RT buffer, 0.5 mM dNTP, 0.5 mM
poly24dT, 5 mM N9, 20 U RNase inhibitor (BIO BASIC INC.)
and 100 U M-MLV(H-) reverse transcriptase (Promega). The
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for 60 min and 70uC for 15 min to inactivate the enzyme. The
reverse transcription (RT) product for each sample was used to
create three dilutions: 4-fold, 20-fold and 40000-fold. Human
genomic DNA from Promega (Catalog No. G152A) was serially
diluted as the input DNA for the construction of standard curves
as described in Jiang et al. [33]. The copy number of each gene in
the input standard genomic DNA was calculated by multiplying
the DNA amount and N0 (the copy number of the corresponding
gene per nanogram human genomic DNA). N0 was 280 for all
P450s and transcription factor genes assuming that there were only
2 copies in each cell (Qiagen Genomic DNA Handbook). For the
three reference genes, N0 was 1660 for GAPDH, 4200 for ACTB
and 22400 for 18S rRNA. These three numbers were estimated by
comparing standard curves of these reference genes and those of
genes with 2 copies per genome (data not shown). The cDNA
molecule numbers of the 14 target genes and 3 reference genes
(18S rRNA, GAPDH and ACTB) in the RT products were
determined using the absolute quantification program of the
SDS2.0 software on an ABI7900 machine (Applied Biosystems).
The expression levels of the 14 target genes and 2 reference genes
(GAPDH and ACTB) were normalized to 18S rRNA by dividing the
cDNA molecule number of each target gene by that of 18S rRNA
and multiplying by 10
7. Each real time PCR reaction included 16
QuantiTect SYBR Green PCR Master Mix (Qiagen Inc.), 0.3 mM
each primer and 2 ml of diluted RT product (40000-fold dilution
for 18S rRNA and 20-fold dilution for other targets) or serially
diluted standard genomic DNA. The PCR program was 95uC for
15 min followed by 40 cycles of 94uC for 15 s, 57uC for 30 s and
72uC for 30 s.
Quantification of CYP2D6 copy number
Two primer pairs specific for CYP2D6 were designed to amplify
different fragments, and one primer pair was designed for
ribonuclease P RNA component H1 (RPPH1). The primer
sequences and amplicon sizes are listed in Table S3. The molecule
quantity of CYP2D6 and RPPH1 genes in 2 ml DNA samples were
separately determined as described above. The copy number of
CYP2D6 in the control DNA from Promega (Cat. No. G152A) was
estimated to be 2 by comparing the standard curve of CYP2D6
with that of RPPH1 (data not shown). Two measurements
obtained using different primer pairs were averaged to obtain
the quantity of CYP2D6 molecules. The CYP2D6 copy number was
estimated by rounding the ratio of the quantity of CYP2D6
molecules to that of RPPH1.
SNP Genotyping
In total, 15 SNPs in 9 genes were selected and typed in 96 DNA
samples extracted from liver tissue samples using the Multiplex
SNaPshot kit (Applied Biosystems Inc.) (Table S2). For the
CYP1A1, CYP1A2, CYP2C9, CYP2C19 and CYP3A4 genes, two
SNPs within the gene with low linkage disequilibrium (LD)
(r
2,0.5) and high minor allele frequency (MAF) (.20%) were
selected. LD and MAF were calculated from genotyping data
released by the HapMap project (http://www.hapmap.org). These
ten SNPs were also typed in heterozygous cDNA samples as
markers to determine allelic expression ratios. Rs776746 in
CYP3A5 contains the CYP3A5*3 allele, which causes improper
splicing and results in a nonfunctional, truncated protein. The
selected SNPs in HNF1A and AHR are non-synonymous
(rs1169288, rs2464196 and rs2066853). Three multiple PCR
and extension panels were designed for the SNaPshot reactions. A
10 ml mixture was prepared for each multiple PCR reaction and
included 16HotStarTaq buffer, 2.8 mM Mg
2+, 0.2 mM dNTP,
0.1–0.3 mM primers, 0.3 U HotStarTaq polymerase (Qiagen Inc.)
and 1 ml template DNA. The cycling program was 95uC for
15 min; 11 cycles of 94uC for 20 s, 62uC 20.5uC/cycle for 40 s
and 72uC for 80 s; 25 cycles of 94uC for 20 s, 56uC for 30 s and
72uC for 80 s and 72uC for 5 min. The PCR products were
purified with the Exo I and SAP enzymes, and subsequent
SNaPshot extension was carried out as described in the
manufacturer’s protocol. Extension products were separated by
gel electrophoresis and analyzed using the ABI3730XL (Applied
Biosystems) system. Data collected on the ABI3730XL system
were analyzed with GeneMapper 4.0.
Measurement of allelic expression ratios
All heterozygous cDNA samples and 5 heterozygous DNA
samples for each marker SNP in the CYP1A1, CYP1A2, CYP2C9,
CYP2C19 and CYP3A4 genes were subjected to single SNaPshot
reactions. Four-fold dilutions of the cDNA samples were used for
amplification of fragments containing intronic SNPs, and twenty-
Table 1. Contributions of four major determinants to the variability in mRNA levels of P450 genes.
Global Regulators
1 P450-specific Regulators
2 Environmental Factors
3 Cis-acting Genetic Variants
4
CYP1A1 ** NS **** *
CYP1A2 *** * **** *
CYP2C9 **** *** *** NS
CYP2C19 ** ** *** *
CYP2D6 * ** NS ***
CYP3A4 *** ** *** NS
CYP3A5 *** NS NS ***
NS denotes not significant. The number of asterisks (*) corresponds to the degree of contribution by different determinants.
1: The number of asterisks (*) was determined based on the correlation coefficients between the mRNA level of GAPDH and that of each P450 gene (one asterisk for a
rho score of approximately 0.2).
2: The number of asterisks (*) was determined based on the correlation coefficients between the mRNA levels of P450 regulator genes and that of each P450 gene (one
asterisk for a rho score of approximately 0.2).
3: The number of asterisks (*) was determined by the correlation coefficients between the mRNA levels of P450 genes under coregulation (one asterisk for a rho score of
approximately 0.2).
4: The number of asterisks (*) was arbitrarily determined based on the allelic expression ratios (for CYP1A1, CYP1A2 and CYP2C19) or the correlation coefficients between
the mRNA level and copy number or some SNPs (for CYP2D6 and CYP3A5).
doi:10.1371/journal.pone.0024900.t001
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including PCR amplification, SNaPshot extension, electrophoretic
separation and data analysis was similar to that described in the
above paragraph, except that only 2.0 mM Mg
2+ and one pair of
primers were included in the PCR reaction, and a single extension
primer was added in the SNaPshot extension reaction. Data
collected on the ABI3730XL were analyzed with GeneMapper
4.0, and the peak height for each allele was exported for further
analysis. The allelic expression ratio was determined by the peak
height ratio of two alleles in the cDNA samples divided by the
average peak height ratio in five DNA samples that were assumed
to have a 1:1 ratio of the two alleles. The basic rationale for
measurement of allelic expression ratio is illustrated in Fig. 6.
The allelic expression imbalance (AEI) assay was carried out by
detecting the expression ratio of two alleles in heterozygous cDNA
samples in which the expression level of the two alleles were
controlled by each other. Fig. 6 illustrates the basic concept of this
assay using the single fluorescent-labeled nucleotide extension
method (SNaPshot, ABI). Theoretically, this assay can significantly
reduce the noise that results from variations in activity of
regulatory factors and improve the sensitivity of detection.
Statistical analysis
SPSS VERSION 15.0 (SPSS Inc., Chicago, IL) was used for
statistical analyses and for BOXPLOT construction. Both the
Kruskal-Wallis test and ANOVA were performed to examine the
associations between genotype and mRNA content. Pearson’s or
Spearman’s rho correlation coefficients between mRNA levels or
between the copy number and mRNA level of CYP2D6 were
identified using bivariate regression analysis. Multivariate logistic
regression was used to adjust for age and smoking history. The
UPGMA tree for seven P450s and seven regulator genes was
constructed using the MEGA4 program based on the pairwise
Spearman’s rho correlation coefficient data.
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